Loading...
•
Feb 29, 2020
AngioDynamics Q3 2020 Earnings Report
AngioDynamics' Q3 2020 financial results were announced, showing a net sales increase of 6.5% compared to the prior-year quarter.
Key Takeaways
AngioDynamics reported a 6.5% increase in net sales for the third quarter of fiscal year 2020, reaching $69.8 million. The company's gross margin was 57.8%, a slight decrease of 40 basis points year over year. The company experienced a net loss from continuing operations of $5.7 million, or a loss of $0.15 per share, while adjusted earnings per share were $0.01. Due to the uncertainty created by the COVID-19 pandemic, management is withdrawing its fiscal year 2020 financial guidance.
Net sales increased 6.5% to $69.8 million compared to the prior-year quarter.
Gross margin declined 40 basis points to 57.8% year over year.
GAAP loss per share was $0.15, with adjusted earnings per share at $0.01.
PATHFINDER I Registry was launched to evaluate the AURYON™ Atherectomy System's performance.
Fiscal year 2020 financial guidance was withdrawn due to COVID-19 pandemic uncertainty.
Revenue by Geographic Location
Forward Guidance
Due to the ongoing pandemic, health systems are prioritizing the care of COVID-19 patients, impacting certain procedures and creating uncertainty, leading management to withdraw its fiscal year 2020 financial guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...